Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Exercise and Health Education for Musculoskeletal Health in Industrial Workers

NCT07844707 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2026-09-22
Last updated
2026-10-02

Condition(s) studied

Work-Related Musculoskeletal Disorders

Investigational drug(s) / intervention(s)

Health EducationTailored Exercise Programme

Health Education: One face-to-face health education session covering pain and coping/self-efficacy strategies, strength exercise, aerobic exercise, mobility, active breaks, sleep hygiene and healthy habits, stress management and emotional well-being, adherence and motivation, and a final discussion and review.

Tailored Exercise Programme: Participants will receive the same face-to-face health education session as the reference group, covering pain and coping/self-efficacy strategies, strength and aerobic exercise, mobility, active breaks, sleep hygiene and healthy habits, stress management and emotional well-being, adherence and motivation. In addition, participants will complete a tailored exercise programme consisting of 8 supervised face-to-face exercise sessions and 8 asynchronous home-based exercise session, corresponding to one face-to-face and one home-based session per week. Exercises will focus on general mobility and stability of the neck, wrist/hand, shoulder and thoracolumbar spine, as well as strengthening of the upper and lower limbs. Exercise difficulty and repetitions may be individually adapted according to each participant's response, perceived difficulty and tolerance. The home-based session will be delivered asynchronously through the RehBody digital platform.

Study summary

This prospective, non-randomised interventional study aims to assess changes in musculoskeletal health, pain and physical activity among industrial workers following a health education and exercise programme adapted to their baseline musculoskeletal profile.

Workers from production lines 8 and 9 at Profand Zaragoza will be allocated to one of two groups according to their baseline musculoskeletal symptoms, assessed using the Nordic Musculoskeletal Questionnaire. The reference group will receive a health education session, while workers with a higher baseline musculoskeletal burden will receive the same health education session together with a specific exercise programme consisting of supervised face-to-face and asynchronous home-based sessions.

The primary outcome is perceived pain intensity measured using the Numeric Rating Scale (NRS). Secondary outcomes include musculoskeletal symptoms and physical activity. In the specific intervention group, health-related quality of life and physical function will also be assessed. Outcomes will be evaluated at baseline, after the intervention and at three-month follow-up. Changes over time will be analysed separately within each group.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Current employment contract with Profand Zaragoza covering the full duration of study participation, including the follow-up period. * Age between 18 and 65 years, inclusive. * Availability to participate in the scheduled study sessions. * Written informed consent provided before enrolment. Exclusion Criteria: * Uncontrolled musculoskeletal, neurological, cardiovascular, respiratory, or systemic disease that contraindicates physical exercise. * Acute musculoskeletal injury, recent surgery, or traumatic condition that substantially limits participation in the physical assessments or exercise programme. * Current pregnancy. * Temporary work incapacity due to illness during the intervention period. * Physical or functional limitation preventing the participant from performing physical exercise independently and safely, even after individual adaptation of the programme by the research team. If there is uncertainty regarding exercise safety, medical assessment will be recommended before inclusion. * Cognitive or communication impairment preventing the participant from understanding the study information, providing valid informed consent, or adequately following the instructions for the assessments and exercises.

Primary outcome measure(s)

  • Change in pain intensity assessed with the Numeric Rating Scale (NRS) — Baseline, immediately after completion of the intervention period, and 3 months after the post-intervention assessment
    Perceived general pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Changes from baseline will be assessed after the intervention and at follow-up.

Trial sites (1)

FacilityCityRegionStatus
Profand Zaragoza. Bari, 3 Zaragoza Zaragoza Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07844707 on ClinicalTrials.gov ↗ ← All trials in Spain